haloperidol has been researched along with Metabolic Syndrome in 7 studies
Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.
Metabolic Syndrome: A cluster of symptoms that are risk factors for CARDIOVASCULAR DISEASES and TYPE 2 DIABETES MELLITUS. The major components of metabolic syndrome include ABDOMINAL OBESITY; atherogenic DYSLIPIDEMIA; HYPERTENSION; HYPERGLYCEMIA; INSULIN RESISTANCE; a proinflammatory state; and a prothrombotic (THROMBOSIS) state.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To determine whether the prescription of aripiprazole, compared with olanzapine and haloperidol, was associated with a lower frequency of metabolic syndrome (MS) and treatment discontinuation at 1 year." | 9.22 | Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. ( Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M, 2016) |
| "Haloperidol or clozapine was orally fed to male and female Sprague Dawley rats for 12 weeks, and body weight gain, food and water intake were measured." | 7.79 | The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model. ( Bouvier, ML; Gaebel, W; Henning, U; Schmitt, A; Schneider-Axmann, T; von Wilmsdorff, M, 2013) |
| "To determine whether the prescription of aripiprazole, compared with olanzapine and haloperidol, was associated with a lower frequency of metabolic syndrome (MS) and treatment discontinuation at 1 year." | 5.22 | Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol. ( Barbato, A; D'Avanzo, B; Parabiaghi, A; Tettamanti, M, 2016) |
| "Haloperidol or clozapine was orally fed to male and female Sprague Dawley rats for 12 weeks, and body weight gain, food and water intake were measured." | 3.79 | The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model. ( Bouvier, ML; Gaebel, W; Henning, U; Schmitt, A; Schneider-Axmann, T; von Wilmsdorff, M, 2013) |
| "We recruited 109 patients with schizophrenia treated with clozapine or haloperidol and evaluated their body mass index (BMI), waist circumference, blood pressure, and fasting triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), fasting plasma glucose, insulin, RBP4, total adiponectin, and HMW adiponectin levels." | 3.77 | Association of plasma retinol-binding protein-4, adiponectin, and high molecular weight adiponectin with metabolic adversities in patients with schizophrenia. ( Chen, CH; Chen, PY; Chiu, CC; Huang, MC; Liu, HC; Lu, ML, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Bouvier, ML | 2 |
| Fehsel, K | 1 |
| Schmitt, A | 2 |
| Meisenzahl-Lechner, E | 1 |
| Gaebel, W | 2 |
| von Wilmsdorff, M | 2 |
| Aly El-Gabry, DM | 1 |
| Abdel Aziz, K | 1 |
| Okasha, T | 1 |
| Azzam, H | 1 |
| Okasha, A | 1 |
| Parabiaghi, A | 1 |
| Tettamanti, M | 1 |
| D'Avanzo, B | 1 |
| Barbato, A | 1 |
| Cohen, D | 1 |
| de Hert, M | 1 |
| Chen, PY | 1 |
| Huang, MC | 1 |
| Chiu, CC | 1 |
| Liu, HC | 1 |
| Lu, ML | 1 |
| Chen, CH | 1 |
| Henning, U | 1 |
| Schneider-Axmann, T | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
1 review available for haloperidol and Metabolic Syndrome
| Article | Year |
|---|---|
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
1 trial available for haloperidol and Metabolic Syndrome
| Article | Year |
|---|---|
Metabolic syndrome and drug discontinuation in schizophrenia: a randomized trial comparing aripiprazole olanzapine and haloperidol.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Female; Follow-Up Studies; Haloperidol; | 2016 |
5 other studies available for haloperidol and Metabolic Syndrome
| Article | Year |
|---|---|
Sex-dependent effects of long-term clozapine or haloperidol medication on red blood cells and liver iron metabolism in Sprague Dawley rats as a model of metabolic syndrome.
Topics: Animals; Antipsychotic Agents; Clozapine; Erythrocytes; Female; Haloperidol; Humans; Iron; Liver; Ma | 2022 |
Antipsychotic Polypharmacy and Its Relation to Metabolic Syndrome in Patients With Schizophrenia: An Egyptian Study.
Topics: Adult; Antipsychotic Agents; Cross-Sectional Studies; Delayed-Action Preparations; Drug Therapy, Com | 2018 |
[Reaction on 'Antipsychotics and metabolic abnormalities in children and adolescents; a review of the literature and some recommendations'].
Topics: Adolescent; Antipsychotic Agents; Child; Energy Metabolism; Evidence-Based Medicine; Haloperidol; Hu | 2010 |
Association of plasma retinol-binding protein-4, adiponectin, and high molecular weight adiponectin with metabolic adversities in patients with schizophrenia.
Topics: Adiponectin; Adult; Antipsychotic Agents; Blood Pressure; Body Mass Index; Clozapine; Female; Halope | 2011 |
The sex-dependent impact of chronic clozapine and haloperidol treatment on characteristics of the metabolic syndrome in a rat model.
Topics: Adiposity; Animals; Antipsychotic Agents; Blood Glucose; Body Weight; Clozapine; Drinking; Eating; F | 2013 |